Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on March 28, 2024. The filing serves to announce the Company's results of operations for the fiscal year ended December 31, 2023. The Company's common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K acts as a notification that the results were issued via a press release (Exhibit 99.1), but the detailed financial data is not embedded in the text of this specific document.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the text provided. It references the full year 2023 results contained in the attached press release.
Guidance, Outlook, and Risks
The text does not provide specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 28, 2024) for the actual numerical results of the fiscal year ended December 31, 2023.
- Verify the Company's cash position and burn rate, as these are critical for a pre-revenue or early-stage biopharma entity, though not listed in this summary text.
- Confirm the status of the Company's clinical development programs and any regulatory milestones achieved in 2023.
- Check for any updates on debt obligations or liquidity events mentioned in the full press release.